Terms: = Pancreatic cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
543 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).
Arai H; Tsuda T; Sunakawa Y; Shimokawa M; Akiyoshi K; Tokunaga S; Shoji H; Kunieda K; Kotaka M; Matsumoto T; Nagata Y; Mizukami T; Mizuki F; Danenberg KD; Boku N; Nakajima TE
Cancer Med; 2024 Apr; 13(7):e7107. PubMed ID: 38591098
[TBL] [Abstract] [Full Text] [Related]
3. Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib.
Ge W; Wang Y; Quan M; Mao T; Bischof EY; Xu H; Zhang X; Li S; Yue M; Ma J; Yang H; Wang L; Yu Z; Wang L; Cui J
Mol Cancer; 2024 Mar; 23(1):48. PubMed ID: 38459558
[TBL] [Abstract] [Full Text] [Related]
4. Twelve-month progression-free survival with sotorasib and panitumumab in KRAS G12C mutant metastatic colorectal cancer.
Kavgaci G; Dizdar O; Yalcin S
Anticancer Drugs; 2024 Jun; 35(5):459-461. PubMed ID: 38451823
[TBL] [Abstract] [Full Text] [Related]
5. SERPINE2 promotes liver cancer metastasis by inhibiting c-Cbl-mediated egfr ubiquitination and degradation.
Zhang S; Jia X; Dai H; Zhu X; Song W; Bian S; Wu H; Chen S; Tang Y; Chen J; Jin C; Zhou M; Xie H; Zheng S; Song P
Cancer Commun (Lond); 2024 Mar; 44(3):384-407. PubMed ID: 38407942
[TBL] [Abstract] [Full Text] [Related]
6. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial.
Zhang D; Benedikt Westphalen C; Quante M; Waldschmidt DT; Held S; Kütting F; Dorman K; Heinrich K; Weiss L; Boukovala M; Haas M; Boeck S; Heinemann V; Probst V
Eur J Cancer; 2024 Apr; 201():113926. PubMed ID: 38401449
[TBL] [Abstract] [Full Text] [Related]
7. Cannabigerol Induces Autophagic Cell Death by Inhibiting egfr-RAS Pathways in Human pancreatic Ductal Adenocarcinoma Cell Lines.
Zeppa L; Aguzzi C; Morelli MB; Marinelli O; Giangrossi M; Luongo M; Amantini C; Santoni G; Nabissi M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396679
[TBL] [Abstract] [Full Text] [Related]
8. PW06 suppresses cancer cell metastasis in human pancreatic carcinoma MIA PaCa-2 cells via the inhibitions of p-Akt/mTOR/NF-κB and MMP2/MMP9 signaling pathways in vitro.
Huang YP; Yeh CA; Ma YS; Chen PY; Lai KC; Lien JC; Hsieh WT
Environ Toxicol; 2024 May; 39(5):2768-2781. PubMed ID: 38264921
[TBL] [Abstract] [Full Text] [Related]
9. Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions.
Liu SV; Frohn C; Minasi L; Fernamberg K; Klink AJ; Gajra A; Savill KMZ; Jonna S
Lung Cancer; 2024 Feb; 188():107469. PubMed ID: 38219288
[TBL] [Abstract] [Full Text] [Related]
10. Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites.
Dayton TL; Alcala N; Moonen L; den Hartigh L; Geurts V; Mangiante L; Lap L; Dost AFM; Beumer J; Levy S; van Leeuwaarde RS; Hackeng WM; Samsom K; Voegele C; Sexton-Oates A; Begthel H; Korving J; Hillen L; Brosens LAA; Lantuejoul S; Jaksani S; Kok NFM; Hartemink KJ; Klomp HM; Borel Rinkes IHM; Dingemans AM; Valk GD; Vriens MR; Buikhuisen W; van den Berg J; Tesselaar M; Derks J; Speel EJ; Foll M; Fernández-Cuesta L; Clevers H
Cancer Cell; 2023 Dec; 41(12):2083-2099.e9. PubMed ID: 38086335
[TBL] [Abstract] [Full Text] [Related]
11. Lovastatin treatment Inducing Apoptosis in Human pancreatic cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria.
Gyoten M; Luo Y; Fujiwara-Tani R; Mori S; Ogata R; Kishi S; Kuniyasu H
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069135
[TBL] [Abstract] [Full Text] [Related]
12. SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma.
Man KF; Zhou L; Yu H; Lam KH; Cheng W; Yu J; Lee TK; Yun JP; Guan XY; Liu M; Ma S
Nat Commun; 2023 Nov; 14(1):7863. PubMed ID: 38030644
[TBL] [Abstract] [Full Text] [Related]
13. Tetrahydrobenzothiophene derivatives ameliorate Mia PaCa-2 cell progression and induces apoptosis via inhibiting egfr2 tyrosine kinase signal.
Rahman A; Sandeep Kumar Jain R; Meghana P; Nippu BN; Manjunatha KS; Rajaput PS; Kumaraswamy HM; Satyanarayan ND
Bioorg Chem; 2024 Feb; 143():106968. PubMed ID: 38007893
[TBL] [Abstract] [Full Text] [Related]
14. Immunofluorescence profiling of collagen subtypes is a predictor of treatment outcomes in pancreatic cancer.
Obaid G; Eroy M; Zhao J; Bano S; Mino-Kenudson M; Hasan T
J Photochem Photobiol B; 2024 Jan; 250():112811. PubMed ID: 38000171
[TBL] [Abstract] [Full Text] [Related]
15. Radiation-Activated Cobalamin-Kinase Inhibitors for treatment of pancreatic Ductal Adenocarcinoma.
Gendron LN; Sheveland CG; Gunn JR; Pogue BW; Shell TA; Shell JR
Mol Pharm; 2024 Jan; 21(1):137-142. PubMed ID: 37989273
[TBL] [Abstract] [Full Text] [Related]
16. Phase I/IIa Trial in Advanced pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, egfr-Targeted Nanocells and Glycolipid-Packaged Nanocells.
Ganju V; Marx G; Pattison S; Amaro-Mugridge NB; Zhao JT; Williams BRG; MacDiarmid JA; Brahmbhatt H
Clin Cancer Res; 2024 Jan; 30(2):304-314. PubMed ID: 37976042
[TBL] [Abstract] [Full Text] [Related]
17. An innovative nanoformulation utilizing tumor microenvironment-responsive PEG-polyglutamic coating and dynamic charge adjustment for specific targeting of ER stress inducer, microRNA, and immunoadjuvant in pancreatic cancer: In vitro investigations.
Li CY; Chou TF; Lo YL
Int J Biol Macromol; 2024 Jan; 254(Pt 2):127905. PubMed ID: 37939778
[TBL] [Abstract] [Full Text] [Related]
18. Integrated PK/PD Modeling Relates Smoothened Inhibitor Biomarkers to The Heterogeneous Intratumor Disposition of Cetuximab in pancreatic cancer Tumor Models.
Wang J; Chen T; Ruszaj DM; Mager DE; Straubinger RM
J Pharm Sci; 2024 Jan; 113(1):72-84. PubMed ID: 37844759
[TBL] [Abstract] [Full Text] [Related]
19. Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRAS
Kataoka M; Kitazawa M; Nakamura S; Koyama M; Yamamoto Y; Miyazaki S; Hondo N; Tanaka H; Soejima Y
Anticancer Res; 2023 Oct; 43(10):4341-4348. PubMed ID: 37772552
[TBL] [Abstract] [Full Text] [Related]
20. 20 years since the approval of first egfr-TKI, gefitinib: Insight and foresight.
Singh S; Sadhukhan S; Sonawane A
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188967. PubMed ID: 37657684
[TBL] [Abstract] [Full Text] [Related]
[Next]
